Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20548719 | 0.93 | TOP2A (0.50) | GAAALDH1A1KMT2AL3MBTL1ALOX15 | |
| SCHEMBL20548706 | 0.93 | TOP2A (0.50) | GAAALDH1A1KMT2AL3MBTL1ALOX15 | |
| SCHEMBL20548509 | 0.93 | GAA (0.44) | GAAALDH1A1MEN1KMT2AVCAM1 | |
| SCHEMBL20548878 | 0.88 | ALDH1A1 (0.51) | GAAALDH1A1MEN1KMT2ALPAR1 | |
| SCHEMBL20548732 | 0.87 | GAA (0.50) | GAAALDH1A1MEN1KMT2ALPAR1 | |
| SCHEMBL20548724 | 0.86 | KMT2A (0.49) | GAAALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL20548507 | 0.84 | GAA (0.48) | GAAALDH1A1MEN1KMT2ALPAR1 | |
| SCHEMBL25261611 | 0.83 | ALDH1A1 (0.52) | GAAALDH1A1MEN1KMT2ALPAR1 | |
| SCHEMBL20548726 | 0.83 | ALDH1A1 (0.51) | GAAALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL20548875 | 0.83 | CA1 (0.48) | GAAALDH1A1MEN1KMT2AVCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2019-01-24 | — | — | US | claimed |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2023-08-29 | — | — | US | disclosed |
| US-20210008022-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10786481-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | BIOMEDICAL ANAYLSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2020-09-29 | — | — | US | disclosed |
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2019-01-24 | — | — | US | disclosed |
| EP-3398934-A1 | HYDROQUINONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION IN TUMOUR RESISTANCE OR IMMUNOMODULATION | Biomedical Analysis Center Academy of Military Medical Sciences (CN) | 2018-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190022049-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | WEE2, WEE1, NQO1 | GAA 3131/4885ALDH1A1 366/4885MEN1 1723/4885 |
| US-20210008022-A1 | HYDROQUINONE COMPOUNDS, PREPARATION METHODS THEREFOR, AND USE IN ANTI-TUMOR OR IMMUNOMODULATION THERAPY | WEE2, WEE1, NQO1 | GAA 2920/4885ALDH1A1 340/4885MEN1 1518/4885 |
| US-10786481-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | WEE2, WEE1, NQO1 | GAA 3131/4885ALDH1A1 366/4885MEN1 1723/4885 |
| US-11738000-B2 | Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy | WEE2, WEE1, NQO1 | GAA 2920/4885ALDH1A1 340/4885MEN1 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.